Search
acalabrutinib (Calquence)
Indications:
- mantle cell lymphoma (breakthrough therapy designation)
- chronic lymphocytic leukemia
- small lymphocytic lymphoma
Dosage:
- 100 mg PO every 12 hours [2]
- continue until disease progression or unacceptable toxicity
Capsule & tablet
Mechanism of action:
- Bruton tyrosine kinase inhibitor
- prevents activation of the B-cell antigen receptor signaling pathway [1]
Interactions
drug adverse effects of tyrosine kinase inhibitor(s)
General
small inhibitory antineoplastic agent (ib drug)
tyrosine kinase inhibitor
Database Correlations
PUBCHEM cid=71226662
References
- PubChem: 71226662
- Bankhead C.
OncoBreak: Terms of Life; FDA Approval Flurry; Gums and Cancer.
News, features, and commentary about cancer-related issues
MedPage Today. August 03, 2017
https://www.medpagetoday.com/PublicHealthPolicy/Ethics/67048
- Windle ML.
FDA New Drug and Biologic Approvals -- 2017 Year-in-Review
Medscape - Jan 11, 2018.
https://reference.medscape.com/viewarticle/890871
- U.S. Food and Drug Administration.
Novel Drug Approvals for 2017.
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
- Wang M, Rule S, Zinzani PL et al
Acalabrutinib in relapsed or refractory mantle cell lymphoma
(ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Lancet. 2017 Dec 11. pii: S0140-6736(17)33108-2. [Epub ahead of print]
PMID: 29241979
- Otto MA
FDA Approves Tablet Formulation of Acalabrutinib (Calquence) for CLL, SLL, and MCL.
Medscape. Aug 5, 2022
https://www.medscape.com/viewarticle/978732